NEW YORK, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

March 10, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the ...

Caribou Biosciences, Inc. (CRBU) stock has tumbled to a 52-week low, reaching a price level of just $0.71. According to... Caribou Biosciences Inc. (CRBU) stock has tumbled to a 52-week low ...

Caribou Biosciences Inc. (CRBU) stock has tumbled to a 52-week low, touching down at $1.49. This latest price point marks a significant drop for the biotechnology company, which has experienced a ...

Caribou Biosciences (NASDAQ:CRBU – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports.

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.39 per share a year ago.

About Caribou Biosciences, Inc. Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with ...

US Trade Policy: Wide-ranging Tariff Increases Heighten Global Credit RiskThu, 10 Apr 2025 12:20:56 GMT US-China Trade War: Yuan Sinks as US Tariff Pressure Mounts, Eyes on BeijingThu, 10 Apr 2025 ...

March 10, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the ...